Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Training Grammar With Meaning
NCT06250101
Recruiting
This study will enroll children between the ages of 4 and 6 years of age who exhibit significant difficulty developing language skills without any other handicapping conditions. Children will receive standardized language, hearing, and cognitive testing to confirm a diagnosis of developmental language disorder. Children will be enrolled in a half-day summer camp program for six weeks during which they will receive treatment designed to improve their language skills. Children will be seen again a... Read More
Gender:
ALL
Ages:
Between 48 months and 83 months
Trial Updated:
07/22/2024
Locations: The University of Arizona, Tucson, Arizona
Conditions: Language Disorders in Children
Register for Updates
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT00920972
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/19/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Arizona Oncology Associates, PC - NAHOA, Prescott Valley, Arizona
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
BiVACOR® Total Artificial Heart Early Feasibility Study
NCT06174103
Recruiting
The purpose of this study is to assess the feasibility of using the BiVACOR Total Artificial Heart (TAH) System to support adult patients with severe biventricular heart failure, or univentricular heart failure in which left ventricular assist device (LVAD) support is not recommended, who require mechanical circulatory support to sustain life. The BiVACOR TAH System is intended for use as a bridge to transplant (BTT). Feasibility will be assessed by evaluating safety and performance of the BiVAC... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/12/2024
Locations: Banner - University Medical Center Phoenix, Phoenix, Arizona
Conditions: Heart Failure, Biventricular Failure
Register for Updates
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults
NCT04848792
Recruiting
Exercise is the cornerstone of disease prevention and often an important component of treatment. However, the efficacy of an exercise stimulus is reduced with aging. This study will investigate whether adding a treatment with phytonutrients found in cruciferous vegetables can improve the exercise response in older individuals.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/09/2024
Locations: Northern Arizona University, Flagstaff, Arizona
Conditions: Aging Problems
Register for Updates
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
NCT04023331
Recruiting
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Gender:
ALL
Ages:
All
Trial Updated:
07/05/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Register for Updates
Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)
NCT04893837
Recruiting
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/03/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Brain Injuries, Traumatic
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Pharmacogenomics of Warfarin in Hispanics and Latinos
NCT02972385
Recruiting
Warfarin is a commonly used blood thinner to treat and prevent blood clots. It is important to take the right dose of warfarin because too much can increase the risk of bleeding and too little can increase the risk of blood clots. This is why patients are closely monitored especially when they begin warfarin therapy. When clinicians prescribe warfarin, they have to consider different factors such as patient's age, body size, diet, and other medications that can interact with warfarin. Certain g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona
Conditions: Thrombosis, Hemorrhage
Register for Updates
Pharmacogenomics of Heparin-Induced Thrombocytopenia
NCT02717039
Recruiting
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona
Conditions: Heparin-induced Thrombocytopenia
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Banner MD Anderson Cancer Center, Goodyear, Arizona
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Goodyear, Arizona
Conditions: Neoplasms
Register for Updates